$PUMA BIOTECHNOLOGY INC(PBYI)$ Puma Biotechnology (NYSE:PBYI) is off 10% premarket on modest volume (~10K shares). Yesterday, it reported results from a Phase 2 study of neratinib for the treatment of breast cancer. Its therapeutic effect was similar to Herceptin (both administered with paclitaxel).